0000899243-22-031602.txt : 20220920 0000899243-22-031602.hdr.sgml : 20220920 20220920174724 ACCESSION NUMBER: 0000899243-22-031602 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220916 FILED AS OF DATE: 20220920 DATE AS OF CHANGE: 20220920 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Canaan XI L.P. CENTRAL INDEX KEY: 0001712417 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40431 FILM NUMBER: 221254620 BUSINESS ADDRESS: STREET 1: 285 RIVERSIDE AVENUE STREET 2: SUITE 250 CITY: WESTPORT STATE: CT ZIP: 06880 BUSINESS PHONE: 203-855-0400 MAIL ADDRESS: STREET 1: 285 RIVERSIDE AVENUE STREET 2: SUITE 250 CITY: WESTPORT STATE: CT ZIP: 06880 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Canaan Partners XI LLC CENTRAL INDEX KEY: 0001850694 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40431 FILM NUMBER: 221254619 BUSINESS ADDRESS: STREET 1: 2765 SAND HILL ROAD CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 203-855-0400 MAIL ADDRESS: STREET 1: 2765 SAND HILL ROAD CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Day One Biopharmaceuticals, Inc. CENTRAL INDEX KEY: 0001845337 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 832415215 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 395 OYSTER POINT BLVD STE 217 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080-1930 BUSINESS PHONE: 206-913-4300 MAIL ADDRESS: STREET 1: 395 OYSTER POINT BLVD STE 217 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080-1930 FORMER COMPANY: FORMER CONFORMED NAME: Day One Biopharmaceuticals Holding Co LLC DATE OF NAME CHANGE: 20210209 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-09-16 0 0001845337 Day One Biopharmaceuticals, Inc. DAWN 0001712417 Canaan XI L.P. 285 RIVERSIDE AVENUE, SUITE 250 WESTPORT CT 06880 0 0 1 0 0001850694 Canaan Partners XI LLC 285 RIVERSIDE AVENUE, SUITE 250 WESTPORT CT 06880 0 0 1 0 Common Stock 2022-09-16 4 S 0 111585 21.53 D 9307021 D Common Stock 2022-09-16 4 S 0 3722 22.04 D 9303299 D Common Stock 2022-09-19 4 S 0 76725 20.57 D 9226574 D Common Stock 2022-09-20 4 S 0 146404 19.50 D 9080170 D Common Stock 2022-09-20 4 S 0 2266 20.10 D 9077904 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.98 - $21.97, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These shares are held directly by Canaan XI L.P. (the "Canaan Fund"). Canaan Partners XI LLC ("Canaan XI") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.98 - $22.28, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.22 - $21.07, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.06 - $19.85, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.06 - $20.15, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Canaan XI L.P., By: Canaan Partners XI LLC, its general partner, By: /s/ Nancy Levenson, Attorney-in-Fact 2022-09-20 Canaan Partners XI LLC, By: /s/ Nancy Levenson, Attorney-in-Fact 2022-09-20